Newer Potential Pharmacological Targets for Multiple Sclerosis

Early initiation of treatment has delayed the onset of disability progression. [...]there is increased interest in treating to target in MS, particularly targeting no evidence of disease activity. (1)This can make it hard for your brain to send signals to the rest of your body.Multiple sclerosis (MS...

Full description

Saved in:
Bibliographic Details
Published inJournal of pharmaceutical sciences and research Vol. 12; no. 2; pp. 302 - 304
Main Authors Gejalakshmi, S, Harikrishnan, N
Format Journal Article
LanguageEnglish
Published Cuddalore Journal of Pharmaceutical Sciences and Research 01.02.2020
Subjects
Blood-brain barrier
Immune system
Immunology
Inflammation
Memory
Multiple sclerosis
Nervous system
Pathogenesis
Proteins
Spinal cord
Young adults
Online AccessGet full text

Cover

More Information
Summary:Early initiation of treatment has delayed the onset of disability progression. [...]there is increased interest in treating to target in MS, particularly targeting no evidence of disease activity. (1)This can make it hard for your brain to send signals to the rest of your body.Multiple sclerosis (MS), the most prevalent neurological disability, is an autoimmune-mediated disorder that affects the central nervous system (CNS) and often leads to severe physical or cognitive incapacitation as well as neurological problems in young adult Multifocal zones of inflammation due to focal T-lymphocytic and macrophage infiltrations, and oligodendrocyte death are the primary causes of myelin sheath de- struction that result in the formation of CNS plaques composed of inflammatory cells and their products, demyelinated and transected axons, and astrogliosis in both white and gray matter. Discontinuation of NTZ (usually for safety concerns, due to a high risk of progressive multifocal leukoencephalopathy) is still a dramatic moment in MS therapeutic management and no guidelines exist about the ideal exit strategy. [...]the choice of CD20-depleting agents which reduce the high number of circulating B-cells could be useful. Tight junctions are the critical component of the BCNSB as they control paracellular diffusion and maintain the structural and functional polarity of the specialized endothelial cells of the BBB and BSCB. [...]the BCNSB contributes to the homeostasis of the parenchyma of the brain and spinal cord and provides protection against many toxic compounds and pathogens Indeed, the BCNSB is largely impermeable to compounds that
ISSN:0975-1459